317 related articles for article (PubMed ID: 29126905)
1. Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption.
Yamamoto S; Sakurai Y; Harashima H
Int J Pharm; 2018 Jan; 536(1):42-49. PubMed ID: 29126905
[TBL] [Abstract][Full Text] [Related]
2. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system.
Sakurai Y; Hatakeyama H; Sato Y; Hyodo M; Akita H; Ohga N; Hida K; Harashima H
J Control Release; 2014 Jan; 173():110-8. PubMed ID: 24120854
[TBL] [Abstract][Full Text] [Related]
3. Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting.
Sakurai Y; Mizumura W; Murata M; Hada T; Yamamoto S; Ito K; Iwasaki K; Katoh T; Goto Y; Takagi A; Kohara M; Suga H; Harashima H
Mol Pharm; 2017 Oct; 14(10):3290-3298. PubMed ID: 28789523
[TBL] [Abstract][Full Text] [Related]
4. Improved Stability of siRNA-Loaded Lipid Nanoparticles Prepared with a PEG-Monoacyl Fatty Acid Facilitates Ligand-Mediated siRNA Delivery.
Sakurai Y; Mizumura W; Ito K; Iwasaki K; Katoh T; Goto Y; Suga H; Harashima H
Mol Pharm; 2020 Apr; 17(4):1397-1404. PubMed ID: 32091909
[TBL] [Abstract][Full Text] [Related]
5. Optimization of a siRNA Carrier Modified with a pH-Sensitive Cationic Lipid and a Cyclic RGD Peptide for Efficiently Targeting Tumor Endothelial Cells.
Hada T; Sakurai Y; Harashima H
Pharmaceutics; 2015 Sep; 7(3):320-33. PubMed ID: 26389942
[TBL] [Abstract][Full Text] [Related]
6. Functional improvement of an IRQ-PEG-MEND for delivering genes to the lung.
Ishitsuka T; Akita H; Harashima H
J Control Release; 2011 Aug; 154(1):77-83. PubMed ID: 21619903
[TBL] [Abstract][Full Text] [Related]
7. RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment.
Yonenaga N; Kenjo E; Asai T; Tsuruta A; Shimizu K; Dewa T; Nango M; Oku N
J Control Release; 2012 Jun; 160(2):177-81. PubMed ID: 22019557
[TBL] [Abstract][Full Text] [Related]
8. Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells.
Chen CW; Lu DW; Yeh MK; Shiau CY; Chiang CH
Int J Nanomedicine; 2011; 6():2567-80. PubMed ID: 22128247
[TBL] [Abstract][Full Text] [Related]
9. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery.
Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
J Control Release; 2011 Jul; 153(2):141-8. PubMed ID: 21447361
[TBL] [Abstract][Full Text] [Related]
10. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
11. Development of High-Functionality and -Quality Lipids with RGD Peptide Ligands: Application for PEGylated Liposomes and Analysis of Intratumoral Distribution in a Murine Colon Cancer Model.
Suga T; Kato N; Hagimori M; Fuchigami Y; Kuroda N; Kodama Y; Sasaki H; Kawakami S
Mol Pharm; 2018 Oct; 15(10):4481-4490. PubMed ID: 30179010
[TBL] [Abstract][Full Text] [Related]
12. Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats.
Chen Z; Deng J; Zhao Y; Tao T
Int J Nanomedicine; 2012; 7():3803-11. PubMed ID: 22888235
[TBL] [Abstract][Full Text] [Related]
13. Novel antiangiogenic therapy targeting biglycan using tumor endothelial cell-specific liposomal siRNA delivery system.
Maishi N; Sakurai Y; Hatakeyama H; Umeyama Y; Nakamura T; Endo R; Alam MT; Li C; Annan DA; Kikuchi H; Morimoto H; Morimoto M; Akiyama K; Ohga N; Hida Y; Harashima H; Hida K
Cancer Sci; 2022 May; 113(5):1855-1867. PubMed ID: 35266253
[TBL] [Abstract][Full Text] [Related]
14. Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles.
Yamamoto S; Kato A; Sakurai Y; Hada T; Harashima H
J Control Release; 2017 Apr; 251():1-10. PubMed ID: 28192155
[TBL] [Abstract][Full Text] [Related]
15. RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells.
Shan D; Li J; Cai P; Prasad P; Liu F; Rauth AM; Wu XY
Drug Deliv Transl Res; 2015 Feb; 5(1):15-26. PubMed ID: 25787336
[TBL] [Abstract][Full Text] [Related]
16. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells.
Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
Biomaterials; 2013 Jul; 34(22):5617-27. PubMed ID: 23623323
[TBL] [Abstract][Full Text] [Related]
17. Discovery and in vivo evaluation of novel RGD-modified lipid-polymer hybrid nanoparticles for targeted drug delivery.
Zhao Y; Lin D; Wu F; Guo L; He G; Ouyang L; Song X; Huang W; Li X
Int J Mol Sci; 2014 Sep; 15(10):17565-76. PubMed ID: 25268623
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic nanotherapy via active targeting systems to tumors and adipose tissue vasculature.
Sakurai Y; Kajimoto K; Harashima H
Biomater Sci; 2015 Sep; 3(9):1253-65. PubMed ID: 26261854
[TBL] [Abstract][Full Text] [Related]
19. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
[TBL] [Abstract][Full Text] [Related]
20. Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA.
Sakurai Y; Hatakeyama H; Sato Y; Akita H; Takayama K; Kobayashi S; Futaki S; Harashima H
Biomaterials; 2011 Aug; 32(24):5733-42. PubMed ID: 21605898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]